What Does the Future Hold for Chemotherapy with the Use of Lipid-Based Nanocarriers?
Open Access
- 24 December 2019
- journal article
- editorial
- Published by Taylor & Francis in Future Oncology
- Vol. 16 (5) , 81-84
Abstract
No abstract availableKeywords
Funding Information
- the European Research Council (N°709613)
This publication has 22 references indexed in Scilit:
- Lipid Nanovectors to Deliver RNA Oligonucleotides in CancerNanomaterials, 2016
- Multifunctional Nanomaterials and Their Applications in Drug Delivery and Cancer TherapyNanomaterials, 2015
- Transferrin-Conjugated SNALPs Encapsulating 2′-O-Methylated miR-34a for the Treatment of Multiple MyelomaBioMed Research International, 2014
- Nanostructured lipid carriers (NLC): A potential delivery system for bioactive food moleculesInnovative Food Science & Emerging Technologies, 2013
- Stealth Properties to Improve Therapeutic Efficacy of Drug NanocarriersJournal of Drug Delivery, 2013
- Tumor-targeted Chlorotoxin-coupled Nanoparticles for Nucleic Acid Delivery to Glioblastoma Cells: A Promising System for Glioblastoma TreatmentMolecular Therapy Nucleic Acids, 2013
- Doxil® — The first FDA-approved nano-drug: Lessons learnedJournal of Controlled Release, 2012
- Pegylated Phospholipid Micelles Induce Endoplasmic Reticulum-Dependent Apoptosis of Cancer Cells but not Normal CellsACS Nano, 2012
- Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to ClinicCritical Reviews™ in Therapeutic Drug Carrier Systems, 2009
- Lipophilic drug derivatives in liposomesInternational Journal of Pharmaceutics, 1998